Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo

Fig. 5

The combination treatment is mediated by changes in mTOR. a Western blots to detect expression levels and the phosphorylation status of AMPK-associated and mTOR-associated proteins using protein lysates prepared from U251, A549, and MCF7 cells treated with metformin (5 mM), abemaciclib (1.25 µM), or the combination for 48 h. b U251, c A549, and d MCF7 cells were treated with or without different concentrations of metformin for 48 h after knockdown of mTOR. Data are shown as the mean ± SD. *P < 0.01, **P < 0.001 (two-way ANOVA, three technical replicates averaged in each). mTOR expression after knockdown of mTOR through RNA interference in U251, A549, and MCF7 cells

Back to article page